Patient \#1 {#onco12108-sec-1001}
===========

The first case is a 49‐year‐old man with recurrent metastatic colon cancer. At age 45, the patient presented with abdominal pain and was found to have a mass at the hepatic flexure on colonoscopy. Staging computed tomography (CT) showed no evidence of metastatic disease. The patient underwent a right hemicolectomy and biopsy of a peritoneal nodule. Pathology from both the colon resection and peritoneal nodule demonstrated signet ring cell adenocarcinoma (Fig. [1](#onco12108-fig-0001){ref-type="fig"}). Additional initial testing showed that the patient\'s tumor had no mutations at codons 12 and 13 in exon 2 of the KRAS gene and was microsatellite stable (MSS) by polymerase chain reaction. He received FOLFOX and bevacizumab for 12 cycles. The patient had no evidence of disease until almost 2 years later when he developed urinary retention. Workup including cystoscopy revealed a prostate mass. Pathology from subsequent bladder biopsy and transurethral resection of the prostate revealed poorly differentiated adenocarcinoma with mucinous and signet ring cell features compatible with the patient\'s previous colonic primary. He resumed FOLFOX and bevacizumab with stabilization of his disease. At the time of progression, he was enrolled in a clinical trial with FOLFIRI and ziv‐aflibercept. Genomic profiling was performed on the primary colon tumor to assess the patient\'s eligibility for clinical trials and identified mutations in *KRAS (Q61)*, *BRCA2*, *FGFR2*, *MSH2*, *NF1*, *CDK12*, *NTRK3*, *POLE*, *APC*, *ATR*, *CDC73*, *CHD4*, *CTNNA1*, *GRIN2A*, *KDM6A*, *KLHL6*, *LRP1B*, *MAGI2*, *PIK3R1*, *SLIT2*, *SMAD4,* and 71 additional alterations of uncertain significance. The specimen was deemed MSS but revealed an extremely high tumor mutation burden (TMB), with ∼116 mutations per mega base. A course of pembrolizumab was started given the presence of the MSH2 mutation and high TMB, two factors that have been associated with responses to checkpoint inhibitors. Repeat imaging after 12 weeks of therapy, however, showed rapid and clear‐cut progression of disease, and the patient was initiated on regorafenib. The patient continued to experience disease progression and was ultimately transitioned to hospice care.

![Histomorphology images from patients 1 and 2. **(A)**: Histologic appearance of hematoxylin and eosin stained tumor from patient \#1 demonstrating a discohesive mucinous tumor with signet ring morphology without true glandular formation. **(B)**: No discernable proliferation of tumor‐infiltrating lymphocytes (TILs) was noted, and immunohistochemical staining for programmed death‐ligand 1 (PD‐L1) was negative (DAKO Inc., Carpenteria CA, Clone 22C3). **(C)**: Appearance of tumor from patient 2 reveals a more conventional colonic adenocarcinoma, which was moderately differentiated with cribriform growth and irregular glands. **(D)**: While histologically dissimilar from patient 1, here too, the presence of TILs was insignificant and PD‐L1 staining was negative. Immunohistochemical staining for the mismatch repair proteins was retained in both specimens (not shown). All images taken at ×200 total magnification.](onco12108-fig-0001){#onco12108-fig-0001}

Patient \#2 {#onco12108-sec-0002}
===========

The second case is a 56‐year‐old man with untreated hepatitis C, prior intravenous heroin use, and metastatic rectal cancer. He initially presented at age 55 with weight loss, rectal pain, and bleeding. CT scan demonstrated a large centrally necrotic rectal mass, tumor thrombus occluding the left portal vein, as well as multiple perirectal abscesses. Biopsy of the rectal mass done by flexible sigmoidoscopy revealed invasive adenocarcinoma with extensive necrosis (Fig. [1](#onco12108-fig-0001){ref-type="fig"}). The patient subsequently underwent diagnostic laparoscopy with diverting colostomy and incision and drainage of abscesses. He was treated with concurrent capecitabine and radiation. Follow‐up imaging showed decrease in the size of the rectal mass as well as progression of portal vein thrombosis and suspicion of new carcinomatosis. He was then started on capecitabine and oxaliplatin (XELOX) and panitumumab. Follow‐up imaging demonstrated partial response, and he remains on this regimen at the time of writing. Genomic profiling of the primary rectal tumor revealed mutations in *BRCA2*, *ATM*, *PIK3CA*, *APC*, *TP53*, *POLE*, *RAF1*, *ABL2*, *NF1*, *CTNNB1*, *FBXW7*, *NTRK2*, *PTEN*, *ACVR1B*, *ARID1A*, *ATRX*, *CHD2*, *CUL3*, *IRF2*, *KDM5A*, *KEL*, *LRP1B*, *MAP2K4*, *PBRM1*, *PIK3R1*, *PRDM1*, *PRKDC*, *SETD2*, *TET2*, *XPO1*, and an additional 118 variants of uncertain significance. His tumor was RAS wild‐type, MSS, and had an extremely high TMB, with 208.43 mutations per mega base.

Molecular Tumor Board {#onco12108-sec-0003}
=====================

Genotyping Results and Interpretation of the Molecular Results {#onco12108-sec-0004}
--------------------------------------------------------------

These two cases were discussed at a Montefiore Medical Center Molecular Tumor Board in September 2016. This novel entity characterized by a *POLE* mutation and an ultramutated and MSS phenotype was identified, and consideration of immunotherapy or experimental options was recommended based on the findings that are reviewed below.

In these two cases, tumor specimens from formalin fixed paraffin embedded tissue were sent to a Clinical Laboratory Improvement Amendments certified laboratory for genomic profiling using a next‐generation sequencing (NGS) panel, which covers the coding region of 315 "cancer‐related" genes plus introns from 28 genes known to be altered in cancer (FoundOne). In addition to accurate determination of base pair substitutions, in/dels, rearrangements, and copy number changes, microsatellite status and TMB are also defined. Measurement of microsatellite instability (MSI) is done by assessing indel characteristics at 114 homopolymer repeat loci in or near the targeted gene regions. TMB is extrapolated to the whole tumor genome after measuring somatic mutations in the sequenced genes. Mutation rates ≥20/Mb, 6--19/Mb, and ≤5/Mb are reported as high, intermediate, and low, respectively.

The genomic testing for both index patients revealed the samples were MSS but categorized as high TMB. In fact, the mutation rate for both patients was remarkably increased (116/Mb in patient 1 and 208.43/Mb in patient 2), consistent with an ultramutated phenotype. The Cancer Genome Atlas Network (TCGA) 2012 examined 224 colorectal cancer (CRC) tumors with exome capture DNA sequencing and identified two subsets of tumors based on mutation rate \[[1](#onco12108-bib-0001){ref-type="ref"}\]. Eighty‐four percent of cases had a mutation rate \<8.24/Mb and the remaining 16% had mutation rates \>12/Mb, classified as nonhypermutated and hypermutated, respectively. Thirty hypermutated tumors had complete data sets, and, of these, 23 were found to be MSI‐high. The seven hypermutated cases that were not MSI‐high, which accounted for the six cases with the highest mutation rates, all contained missense mutations in the proofreading exonuclease domain of DNA polymerase ɛ (*POLE)*. Among other mutations identified in our two index patients, both contained a *POLE* mutation. The *POLE* mutation reported, p.Val411Leu, is the same for both of our patients, indicating the encoded amino acid at position 411 has changed from a valine to a leucine. Mutation allele frequencies of the POLE mutation were 10% in patient 1 and 24% in patient 2. In both cases, allele frequencies were consistent with a clonal mutation.

Patterns of genes that were recurrently mutated in the TCGA data were also characterized. Fifteen expressed genes were found to be recurrently mutated in the hypermutated CRC and 17 in the nonhypermutated cancers. The patterns and frequency of mutations were significantly different between the two groups. For example, *TP53* and *APC* were mutated significantly more frequently in the nonhypermutated tumors, whereas *TGFBR2* was more frequently mutated in the hypermutated cases. The mutational profile of hypermutated tumors with MLH1 silencing and MSI‐high demonstrated significantly higher rates of frameshift mutations in 28 assessed genes with long mononucleotide repeats in their coding sequences \[[1](#onco12108-bib-0001){ref-type="ref"}\]. Further analysis of the CRCs with *POLE* exonuclease domain mutations (EDM) in the TCGA data demonstrated an increase in all types of base substitutions. C:G\>T:A was the most common mutation type, but compared to other cancers the relative increase in G:C\>T:A was most dramatic \[[2](#onco12108-bib-0002){ref-type="ref"}\].

Functional and Clinical Significance of a *POLE* Mutation in CRC {#onco12108-sec-0005}
----------------------------------------------------------------

High‐fidelity DNA replication in human cells is safeguarded by two pivotal mechanisms: proofreading by the DNA polymerases themselves and DNA mismatch repair (MMR). The chances of new mutations arising during genome replication are thereby drastically limited by the accuracy of DNA replicases in base selection, aided by nearly instant proofreading via built‐in exonuclease function and subsequent MMR for errors escaping proofreading. Germline effects in these genes affecting DNA repair can lead to unique phenotypes characterized by cancer susceptibility syndromes. On the other hand, somatic alterations can provide a recurrent mechanism of carcinogenesis via the accumulation of large number of mutations \[[3](#onco12108-bib-0003){ref-type="ref"}\].

MutS and MutL are proteins which are critical to initiation of mismatch repair and are often mutated in hereditary nonpolyposis colorectal cancer. MMR begins when the MutS heterodimer complex (α or β) recognizes and binds mismatched DNA or insertion/deletion loops (IDL) on the daughter strand of replicating DNA (Fig. [2](#onco12108-fig-0002){ref-type="fig"}). The MutS DNA complex then recruits the MutL heterodimer (consisting of MLH1 and PMS2). A third complex, proliferating cell nuclear antigen and replication factor C, binds MutL and serves as a DNA clamp, activating the endonuclease function of PMS2. Simultaneously, exonuclease 1 function is also activated for excision of the mismatched DNA. DNA ligase then rejoins the replacement nucleotide(s) of the excised mismatch \[[4](#onco12108-bib-0004){ref-type="ref"}\].

![Biochemical basis of POLE deficiency.\
Abbreviations: MMR, mismatch repair; PCNA, proliferating cell nuclear antigen; POL α, DNA polymerase α; POL δ, DNA polymerase δ; POL ɛ, DNA polymerase ɛ.](onco12108-fig-0002){#onco12108-fig-0002}

Heterozygous mutations in any of the four MMR genes, MLH1, MSH2, MSH6, and PMS2, contribute to a state termed MSI. MSI is characterized by deficiency in repair of base‐base mismatches and/or IDL, leading to missense or frameshift mutations, as well as by frequent insertion and deletions especially at homopolymer and dinucleotide repeats. MSI is commonly associated with hereditary nonpolyposis CRC and a high DNA mutational burden in associated cancers ranging from 10 to 100 mutations per Mb \[[4](#onco12108-bib-0004){ref-type="ref"}\], \[[5](#onco12108-bib-0005){ref-type="ref"}\].

Distinct from MMR, proofreading during DNA replication is performed by the exonuclease domains of DNA polymerase δ (Pol δ) and Pol ɛ, which are critical components of the normal DNA replication process that is carried out by several interacting polymerases. Polymerase α initiates DNA synthesis, then Pol ɛ and Pol δ take over replication of the leading and lagging strands of eukaryotic DNA, respectively. During replication, DNA polymerase α (Pol α) and Pol ɛ, via their exonuclease function, detect and replace mismatched bases in the leading strand by checking against the methylated parent strand \[[4](#onco12108-bib-0004){ref-type="ref"}\], \[[6](#onco12108-bib-0006){ref-type="ref"}\], \[[7](#onco12108-bib-0007){ref-type="ref"}\]. This proofreading function improves replication fidelity by 100‐fold or so.

Despite high levels of evolutionary conservation in the exonuclease domain of both genes, the polymerases are susceptible to germline and somatic EDM. *POLE‐*mutated, MSS patients present with high tumor burden due to deficiency in the 3′ to 5′ proofreading functions in the exonuclease domain of the polymerase. Recurrent "hotspot" mutations have been identified in the exonuclease domain of Pol ɛ, and the majority are located along the DNA‐binding pocket---most commonly affecting the P286 amino acid residue. Others, including residue 411, are not predicted to directly interact with DNA. However, in biochemical studies, this clearly leads to deficient proofreading function. Mutations such as V411L are seen repeatedly in these cancers, including our two cases, suggesting an indirect effect on the proofreading function of the exonuclease domain.

Although mutations in *POLE* can be corrected by MMR, the substantial mutation burden simply overwhelms the MMR pathway and demonstrates the characteristic multifaceted oncogenic progression \[[4](#onco12108-bib-0004){ref-type="ref"}\], \[[7](#onco12108-bib-0007){ref-type="ref"}\], \[[8](#onco12108-bib-0008){ref-type="ref"}\]. In addition, many *POLE*‐deficient tumors harbor additional mutations in MMR genes, possibly further contributing to the excessive mutation rate. Overall, the very high mutation rate leads to an average of 5,000 coding sequence mutations in *POLE* cases just in the coding sequence. Many of the recurrent mutations include nonsense changes in APC, MSH6, p53, KRAS, and PIK3CA that are often of types and positions other than common hotspots and might be contributing to overall carcinogenesis as so‐called "mini‐drivers."

In 2010, Yoshida et al. reported the first *POLE* mutation in a human colorectal adenocarcinoma \[[9](#onco12108-bib-0009){ref-type="ref"}\]. Since then, multiple germline and somatic mutations in *POLD1* and *POLE* have been reported, predominantly in endometrial cancer and CRC. Data from The TCGA reported *POLE* mutations in approximately 3% of colorectal and 7% of endometrial cancers \[[1](#onco12108-bib-0001){ref-type="ref"}\]. Genomic profiling found that the majority of tumors with these *POLE* mutations demonstrate very high TMB, often exceeding 100 mutations per Mb. Ultramutated tumors make up 6.4% of low‐grade and 17.4% of high‐grade endometrioid endometrial cancers (ECs) \[[10](#onco12108-bib-0010){ref-type="ref"}\]. As discussed, the specific alterations are distinct from those typically seen in cancers with MSI \[[1](#onco12108-bib-0001){ref-type="ref"}\]. Rare germline mutations in *POLD1* and *POLE* have been described in patients with polymerase proofreading‐associated polyposis, a clinical phenotype quite similar to that of MMR deficiency \[[11](#onco12108-bib-0011){ref-type="ref"}\], \[[12](#onco12108-bib-0012){ref-type="ref"}\]. While germline *POLD1* mutations might be involved in familial cases, there is little evidence to suggest that somatic *POLD1* mutations act as a driver of spontaneous CRC, as seen in *POLE* mutations.

Enhanced immunogenicity and improved clinical outcomes have been reported in endometrial cancer patients with *POLE* mutations \[[13](#onco12108-bib-0013){ref-type="ref"}\]. Recent data suggest similar findings in CRC with *POLE* mutations. Cox regression analysis on pooled data from three clinical trials and multiple patient cohorts detected 66 POLE mutations in 6,517 (1.0%) CRC samples \[[14](#onco12108-bib-0014){ref-type="ref"}\]. *POLE* mutations were associated with young age, male sex, right‐sided tumor location, early disease stage, and absence of MMR deficiency. Furthermore, *POLE* mutations were associated with a reduced risk of disease recurrence (hazard ratio \[HR\] 0.34, *p* = .006), and this association was stronger than that seen with MMR deficiency, which is known to carry a more favorable prognosis, particularly in early‐stage CRC. Immunohistochemical studies also demonstrated increased tumor‐infiltrating lymphocytes in tumors with *POLE* mutations compared with MMR‐proficient tumors, but this finding was not statistically different when compared with MMR‐deficient tumors. Interestingly, a smaller study by Stenzinger et al. did not identify a clear association between *POLE* mutations and clinical outcomes in 431 CRC patients with MSS disease \[[15](#onco12108-bib-0015){ref-type="ref"}\].

Potential Strategies to Target the Pathway {#onco12108-sec-0006}
------------------------------------------

A phase II study of pembrolizumab in 41 patients with advanced cancers concluded that MMR deficiency predicts higher response rates \[[16](#onco12108-bib-0016){ref-type="ref"}\]. Eleven patients had MMR‐deficient CRC, 21 patients had MMR‐proficient CRC, and 9 patients had MMR‐deficient non‐CRC. Both primary endpoints were significant: the immune‐related objective response rate and 20‐week immune‐related progression‐free survival were 40% and 78%, respectively for MMR‐deficient CRC and 0% and 11% for MMR‐proficient CRC. Non‐CRC with MMR‐deficient tumors had similar results to the cohort of MMR‐deficient CRC: 71% immune‐related objective response rate and 67% immune‐related progression free survival rate. Of note, a high mutation burden was associated with prolonged progression‐free survival \[[16](#onco12108-bib-0016){ref-type="ref"}\].

Indeed, several tumor types with high TMB have recently been shown to have better response rates with immune checkpoint inhibitors. The increased tumor‐infiltrating lymphocytes observed in MSI‐high CRC are themselves a sign of immune activation, and it has been hypothesized that the increased mutational burden seen in these tumors could predict immunogenicity and response to immune checkpoint blockade. It is estimated that *POLE* mutated tumors on average have 15‐fold more neoantigens than MSI tumors and 100‐fold more than typical MSS tumors \[[17](#onco12108-bib-0017){ref-type="ref"}\], \[[18](#onco12108-bib-0018){ref-type="ref"}\].

With evidence to support improved response to immune checkpoint blockade in tumors with high mutation rates, it is logical to hypothesize similar responses in the subset of cancers with *POLE* mutations leading to an ultramutated MSS phenotype. There are ongoing clinical trials addressing this question; however, identifying such cases with this potentially meaningful genomic abnormality poses a challenge. Interestingly, a recent study demonstrated that screening for MMR status could be done very reliably using NGS profiling and cutoffs for mutational load \[[19](#onco12108-bib-0019){ref-type="ref"}\]. Out of 224 CRC tumors that underwent NGS profiling (341 gene panel), 100% of the 193 tumors with \<20 mutations were MMR proficient. Twenty‐eight of the 31 tumors with \>20 mutations were MMR deficient, and the remaining three had distinctly higher mutation rates and all harbored the *POLE* P286R mutation. Given that *POLE* mutations are found in a small but relevant portion of CRC, we propose an algorithm that includes screening for such mutations when performing genomic profiling on these tumors (Fig. [3](#onco12108-fig-0003){ref-type="fig"}). Clinical trials targeting programmed cell death 1/programmed death‐ligand 1 (PD‐L1) in a variety of malignancies with *POLE* mutations are ongoing (NCT02912572, NCT02899793, and NCT02658279).

![Proposed algorithm for expanded molecular testing for stage IV colorectal cancer.\
Abbreviations: EGFR, epidermal growth factor receptor; MSI, microsatellite instability; POL δ, DNA polymerase δ; POL ɛ, DNA polymerase ɛ; TMB, tumor mutation burden.](onco12108-fig-0003){#onco12108-fig-0003}

As discussed, tumors with *POLE* EDM display characteristic increases in base substitutions. However, there is evidence that these mutations do not all lead to one unique clinical, pathologic, or molecular phenotype. Ahn et al. examined 28 MSS early‐onset CRC with whole exome sequencing and identified 6 hypermutated cases, 4 of which had the same *POLE* P286R mutation and 2 of which had *POLE* mutations outside the exonuclease domain \[[6](#onco12108-bib-0006){ref-type="ref"}\]. Findings were validated with an expanded cohort of 83 MSS early‐onset CRC, which identified 6 tumors with the same *POLE* P286 mutation. No significant difference was seen in the immune profiles of tumor cells and tumor‐infiltrating lymphocytes with respect to *POLE* mutation status. It would not be surprising that such high rates of mutation might lead to a variety of alterations and drivers of tumorigenesis. This heterogeneity may also prove to be a challenge when applying treatment strategies. Despite the promise of immunotherapy in highly mutated tumors, not all such cancers will respond to checkpoint inhibitor therapy. In our first case, in which no response to immunotherapy was observed, the lack of PD‐L1 staining might suggest primary poor immune recognition, possibly calling for combination immunotherapy for such cases. Alternatively, the exceedingly high mutation rate could lead to subclonal alterations, allowing for rapid adaptation, clonal selection, and subsequent immune evasion.

A potential targeted treatment strategy to consider involves the concept of "synthetic lethality." In a tumor with an underlying defect in DNA repair such as *POLE* mutation, targeting a separate DNA repair mechanism may lead to preferential death of tumor cells. This approach has been investigated using poly(ADP)ribose polymerase (PARP) inhibitors in BRCA gene‐mutated ovarian and breast cancers \[[20](#onco12108-bib-0020){ref-type="ref"}\], \[[21](#onco12108-bib-0021){ref-type="ref"}\]. A phase II study with the PARP inhibitor olaparib did not demonstrate activity in advanced CRC patients with MSS or MSI‐high tumors \[[22](#onco12108-bib-0022){ref-type="ref"}\]. Nonetheless, *POLE*‐deficient cancers encompass a different mechanism of failed DNA repair, and targeted therapies such as these may prove successful in the future.
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